
Knight Therapeutics: A Canadian specialty pharma firm, licensing and offering healthcare products globally.
Knight Therapeutics, founded in Canada, is a specialty pharmaceutical company dedicated to acquiring and licensing pharmaceutical products. Its core mission is to provide innovative healthcare solutions to improve patient outcomes globally. The company focuses on offering a diverse range of healthcare products, targeting various therapeutic areas to meet the needs of the global healthcare industry.
Notable affiliated individuals include key executives and board members with extensive experience in the pharmaceutical sector. Knight Therapeutics has secured investments from reputable financial entities, bolstering its market presence. The company has achieved significant milestones, including successful product launches and strategic partnerships, contributing to its overall impact on global healthcare.

NKT Therapeutics

NeuroTherapeutics Pharma

Kymera Therapeutics
kymeratx.com

Karyopharm Therapeutics
karyopharm.com

Kiniksa Pharmaceuticals
kiniksa.com

KinDex Pharmaceuticals

Manhattan Pharmaceuticals

Katana Pharmaceuticals

KPI Therapeutics

Guardian Therapeutics

Kinaset Therapeutics
kinasettx.com

Cambridge Therapeutic Technologies
Athenen Therapeutics

SphynKx Therapeutics

Kirax
Companies similar to Knight Therapeutics include NKT Therapeutics, NeuroTherapeutics Pharma, Kymera Therapeutics and Karyopharm Therapeutics.
Knight Therapeutics was founded in 1995.
Knight Therapeutics' headquarters is located in Montreal, Quebec, CA.
Knight Therapeutics' most recent funding round was for $38.5M (USD) in December 2022.
As of Dec 23, 2022, Knight Therapeutics has raised a total of $636.3M (USD).
Knight Therapeutics has 768 employees as of Feb 12, 2024.